Disclosures for "The Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) on Patients and Caregivers in the United States "
-
Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Osborne has received publishing royalties from a publication relating to health care.
-
Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen@Janssen. Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Bernitsas has received research support from Roche/Genentech.
-
Ms. Rebeira has stock in Alexion, Astrazeneca Rare Disease.
-
Nicole Betor has received personal compensation for serving as an employee of Avalere.
-
Miss Dodd has received personal compensation for serving as an employee of Avalere Health.
-
Mr. Loreto has nothing to disclose.
-
Miss Olsenolsen has nothing to disclose.
-
Dr. Garduno has received personal compensation for serving as an employee of Avalere.
-
Justin Lee has received personal compensation for serving as an employee of Alexion.
-
Lindsey Przybyl has received personal compensation for serving as an employee of Alexion, AstraZeneca Rare Disease. Lindsey Przybyl has stock in AstraZeneca.
-
Ms. Sullivan has received personal compensation for serving as an employee of EveryLife Foundation for Rare Diseases. An immediate family member of Ms. Sullivan has received personal compensation for serving as an employee of Takeda. Ms. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving as a Policy Advisor with COPD Foundation.
-
Dr. Yu has received personal compensation for serving as an employee of Alexion. Dr. Yu has stock in AstraZeneca.